Quantitative Study on HRCT Phenotype of COPD

Study Overview
=================
Brief Summary
-----------------
To explore the HRCT phenotype of the combined COPD assessment staging system

Detailed Description
-----------------
HRCT can be rapidly and safely deployed has enabled COPD research to move beyond FEV1 by facilitating and amplifying clinical phenotyping measurements, providing quantitative information, and detecting significant responses to therapy even in the absence of significant FEV1 improvements. We explore the HRCT phenotype of the combined COPD assessment staging system,and found that: Airway remodeling occurs in COPD patients. CT shows varying degrees of bronchial wall thickness, area increasing and emphysema as the new GOLD classification Group A-D arising. The GOLD Combined assessment staging system helps doctors choose an individualized treatment for the COPD patients

Official Title
-----------------
Quantitative Study on HRCT Phenotype of the GOLD COPD Assessment Staging

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 40 and 80 (including 40 and 80) It meets the diagnostic criteria for COPD No language communication barriers, or the family members who know the condition can complete the questionnaire on behalf of the patient, and the data are reliable; Voluntarily agree to participate in this study Exclusion Criteria: Older than 80 or younger than 40 Pregnant women Complicating with other lung diseases, such as asthma, pneumonia, bronchiectasis, lung abscess, interstitial lung disease, confirmed and suspected lung cancer of lung shadow, active pulmonary tuberculosis, etc Previous lung surgery Cognitive dysfunction Unable to cooperate with lung function test.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A in GOLD<br>CAT<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year<2； | |
| Group B in GOLD<br>CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year<2 | |
| Group C in GOLD<br>CAT<10、mMRC 0-1、 FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1 | |
| Group D in GOLD<br>CAT≥10、mMRC≥2、FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1 | |
| Control Group<br>not COPD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The severity of emphysema | % low attenuation area <950 HU (LAA %) | Within an average of 3 days after diagnosis of COPD | 
| Indicator A of the severity of airway stenosis | The inner diameter of bronchial (LD) in centimeter | Within an average of 3 days after diagnosis of COPD | 
| Indicator B of the severity of airway stenosis | The bronchial wall thickness in centimeter | Within an average of 3 days after diagnosis of COPD | 
| Indicator C of the severity of airway stenosis | Ratio of thickness and outer diameter (TDR) | Within an average of 3 days after diagnosis of COPD | 
| Indicator D of the severity of airway stenosis | % wall area for bronchial external diameter (WA%) | Within an average of 3 days after diagnosis of COPD | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary disease; chronic obstructive; Phenotype